3.29
+0.44(+15.44%)
Currency In USD
Address
8, rue de la Croix Jarry
Paris, 75013
France
Phone
33 1 81 69 16 00
Website
Sector
Healthcare
Industry
Biotechnology
Employees
216
First IPO Date
March 24, 2015
| Name | Title | Pay | Year Born |
| Dr. David J. D. Sourdive Ph.D. | Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director | 593,156 | 1967 |
| Dr. Andre Choulika Ph.D. | Co-Founder, Chief Executive Officer & Director | 937,539 | 1965 |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer | 0 | N/A |
| Pascalyne Wilson | Director of Communications | 0 | N/A |
| Mr. Jean Charles Epinat Ph.D. | Chief Technological Officer | 0 | N/A |
| Ms. Kyung Nam-Wortman | Executive Vice President & Chief Human Resources Officer | 0 | 1970 |
| Mr. Stephan Reynier M.Sc. | Chief Regulatory & Pharmaceutical Compliance Officer | 0 | 1969 |
| Ms. Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors | 0 | 1982 |
| Mr. Arthur Stril | Chief Financial Officer & Chief Business Officer | 0 | 1989 |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer | 0 | 1963 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.